Search Results for "Sjogren A Belimumab"

09:27 EDT 25th October 2014 | BioPortfolio

Original Source: Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by an increase in BAFF (BLyS) levels and a resulting B cell hyperactivity. B cells are involved in the pathogenesis of SS in both systemic and glandular features, and B cell downregulation may lead to a decrease of disease activity. Moreover, pathogenesis of SS is closed to that of Systemic lupus erythematosus, where Belimumab has been proven to be effective.

Matching Channels


Matching News

Pregnancy Possible in Lupus Patients Taking Belimumab

Successful live births are possible in women with lupus who conceive while taking belimumab, new research shows. Medscape Medical News

Pacific Mercantile Bank Names Robert E. Sjogren Chief Operating Officer

COSTA MESA, Calif., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Pacific Mercantile Bank ("the Bank"), the wholly owned subsidiary of Pacific Mercantile Bancorp (Nasdaq:PMBC), today announced that Robert E. Sjo...

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Revision: 9, Authorised

Link between viral infection and autoimmune disease

Australian scientists have discovered that common viral infections can pave the way to autoimmune disease. Their work was published in the journal Immunity. The research focused on chronic cytomegalo...

Aldeyra raises $12 million in IPO

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) raised $12 million in an IPO through a bumped-up number of shares below its proposed price range. The company sold 1.5 million shares at $8, which values Aldeyr...

Autoimmune Technologies, LLC - Product Pipeline Analysis, 2014 Update

Recently added to the BioPortfolio report store, Autoimmune Technologies, LLC - Product Pipeline Analysis, 2014 Update is a new report from GlobalData published on 2014-07-14. This 23-page report is ...

CHPA Celebrates International Self-Care Day with Event on Capitol Hill

The Consumer Healthcare Products Association (CHPA) is proud to host the first International Self-Care Day (ISCD) event in the United States. The World Self-Medication Industry (W...

Lilly halts development of tabalumab for lupus at phase III

Eli Lilly is to discontinue development of tabalumab for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) owing to disappointing results in two phase III trials.In the ILLU...

Matching PubMed Articles

Update on belimumab for the management of systemic lupus erythematosus.

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS). It is the first biological drug to be licensed and approved by the US FDA and the European Medicines Evaluatio...

Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.

This case report describes two female lupus patients who both received biological treatment with tocilizumab and with belimumab. The disease course was remarkably similar in both cases. Tocilizumab re...

A23: favorable response to belimumab in childhood-onset systemic lupus erythematosus.

Belimumab (Benlysta) is a human monoclonal antibody inhibiting soluble B-lymphocyte stimulator that was approved by the Food and Drug Administration in 2011 for treatment of active, autoantibody-posit...


The classification criteria for Sjogren syndrome: issues for their improvement from the study of a large Italian cohort of patients.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement